SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing extreme price volatility and significant trading halts following a major legal victory against Papaya Gaming, which has sparked intense debate among investors regarding the company's valuation and the potential for a short squeeze. Community sentiment remains deeply polarized, with some bulls pointing to the cash infusion as a catalyst for growth while vocal detractors label the stock a fraudulent "hallt-heavy" trap that systematically prevents retail traders from executing trades.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Markets are exhibiting sharp volatility as investors react to geopolitical tensions in the Middle East, specifically reports of Iranian officials resigning from the negotiating team and intensified naval confrontations. The community is deeply divided between active 'dip buyers' expecting a rapid rebound and bearish traders pointing to the broader energy crisis and conflict risks as catalysts for a deeper pullback.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing extreme intraday volatility driven by ongoing geopolitical tensions and investor frustration over heavy market manipulation. Community sentiment is deeply divided, with many traders debating whether the relentless, low-volume price surges reflect genuine bullish strength or a dangerous, artificial bubble orchestrated by institutional algorithms.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing significant volatility following a quarterly update that highlighted progress on its Eagle Line pilot production and new market engagements beyond the automotive sector, including AI data centers and defense. While some investors are optimistic about the company's commercial validation and potential for a short squeeze, others remain skeptical, pointing to the company's ongoing cash burn and the historical tendency for the stock to experience sharp intraday reversals.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as frustrated investors react to a relentless semiconductor sector rally that has pushed SOXL to record levels while triggering significant decay in bearish positions. The community is sharply divided between those struggling with heavy losses while attempting to DCA or catch a technical bottom and those arguing that the current valuation of semi-conductor equities is disconnected from reality.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing intense retail engagement and volatile price action as traders debate whether the stock is in a sustainable semiconductor super-cycle or a speculative AI bubble nearing a blow-off top. Community discussion is heavily divided between bulls celebrating a record-breaking streak of gains and bears anticipating a violent correction, with many retail participants actively debating the risks of holding a 3x leveraged ETF through upcoming semiconductor earnings.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is facing extreme volatility and intense retail debate as the market reacts to shifting federal cannabis policies and reclassification discussions. Investors remain deeply divided, with many actively monitoring technical support levels and high short interest while clashing over the company's long-term leadership and dilution concerns.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is facing significant selling pressure from its largest shareholder, AE Industrial Partners, which is consistently divesting its stake, causing heavy overhead resistance and volatility despite the company landing frequent defense contracts. The community remains largely bullish on the company's long-term potential as a key player in space infrastructure and drone technology, but remains frustrated by the relentless supply overhang that has consistently capped rallies near the double-digit price level.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing intense volatility after a double-earnings beat was overshadowed by margin concerns, geopolitical headwinds, and broader investor anxiety regarding the impact of AI on SaaS valuations. While the community is deeply divided between those viewing the sell-off as a prime accumulation opportunity for a high-growth asset and those fearing a long-term structural reset, the core debate centers on whether AI serves as a long-term accelerator for enterprise workflows or a margin-crushing threat to software pricing models.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Pessimistic Outlook for ENLV Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Enlivex Therapeutics in a research note issued to...

Research Analysts Set Expectations for ENLV Q1 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.02) per share...

HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock

HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday...

Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Enlivex Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Enlivex Therapeutics Q4 Earnings Call Highlights

Enlivex Therapeutics (NASDAQ:ENLV) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what they described as a dual-engine strategy that combines clinical-stage...

Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $12.85 earnings per share for the quarter, beating analysts' consensus...

<ul><li>Enlivex’s first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation model: A clinical-stage quality longevity program powered by a prediction markets treasury strategy.</li><li>IND clearance follows the positive 3 and 6-month data readout from the Company’s Phase 1/2a multicenter, randomized, double-blind, placebo-controlled clinical trial, which enrolled 134 patients, and demonstrated a robust, durable, clinically meaningful, and statistically significant treatment effect in older patients with knee osteoarthritis.</li></ul>Nes-Ziona, Israel, March 23, 2026 (GLOBE NEWSWIRE) — Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Allocetra™, the Company’s clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA).The FDA’s clearance enables Enlivex to initiate a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040.This is the first regulatory clearance obtained by the Company following the implementation of its dual-engine value creation model, which is centered on the development of a clinical-stage quality longevity program powered by a prediction markets treasury strategy.Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, “We are very pleased to have received FDA clearance to initiate the Phase 2b clinical trial of Allocetra™ in patients with age-related primary knee osteoarthritis. This milestone represents an important step toward our mission of improving the quality of life of an aging population that is suffering from this debilitating disease with poor availability of treatment options. In our previous clinical study, Allocetra™ demonstrated a robust, durable, and clinically meaningful treatment effect lasting at least six months, with increasing benefit observed in older patient populations. We look forward to enrolling the first patients into the Phase 2b and believe Allocetra™ has the potential to address a major unmet medical need for elderly patients suffering from knee osteoarthritis while supporting a strong commercial opportunity for Enlivex.”The Phase 2b trial has been designed to be statistically powered to evaluate key efficacy endpoints, including change from baseline in pain and physical function compared with placebo, measured at three- and six-months following treatment. Additional endpoints include changes in quality-of-life measures and functional mobility assessments.About Enlivex (Nasdaq: ENLV)Enlivex is a quality longevity Company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging with a primary focus on age-related osteoarthritis.In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual-engine structure combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.About Knee OsteoarthritisKnee osteoarthritis (KOA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. There are currently no approved disease modifying therapies; treatment is largely limited to pain relief, intra articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of knee OA patients are 60 years and older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.ENLIVEX CONTACTShachar Shlosberger, CFO Enlivex Ltd. <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=9Rln_Ms_YDeRPyQEv-oocAqcVW9S1vSSlmOHeWY4dao7nXzR7IbvSuoGEwQTnQ1n1EBwJxQAMhb9vYDbQfZKdZpuk5FsnmAIYb__INu_oD4=">shachar@enlivex.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

FDA clears Enlivex’s Phase 2b trial for Allocetra™ to treat age-related knee osteoarthritis.

Others

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday

Enlivex Therapeutics (NASDAQ:ENLV) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-enlivex-therapeutics-ltd-stock...

Enlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Wednesday

Enlivex Therapeutics (NASDAQ:ENLV) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

ENLV
Enlivex Therapeutics Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ENLV News

ENLVEnlivex Therapeutics Ltd